Clinical trialNCT06868485RecruitingPhase 2Interventional

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

SponsorWayshine Biopharm, Inc.Enrollment40Non Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Adjei Alex A., PhD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China
Recruiting
Wuhan Union Hospital
Wuhan, Hubei, China
Recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Recruiting

France

Centre Hospitalier Universitaire (chu) de Rennes - Hopital de Pontchaillou
Rennes, Ille-et-Vilaine, France
Recruiting
Centre Hospitalier Universitaire Chu de Limoges
Limoges, New Aquitaine, France
Recruiting
Chu Bordeaux - Centre Francois Magendie
Pessac, New Aquitaine, France
Recruiting
Centre Francois Baclesse
Caen, Normandy, France
Recruiting
Chu Toulon - Hopital Sainte Musse
Toulon, Var, France
Recruiting

United States

Fomat Oncology
Oxnard, California, United States
Recruiting
Cleveland Clinic Weston Hospital
Weston, Florida, United States
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
Hackensack Meridian Health-Southern Ocean Medical Center
Manahawkin, New Jersey, United States
Recruiting
Cleveland Clinic
Cleveland, Ohio, United States
Recruiting
Upmc Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Recruiting
Txo Central/south, Texas Oncology -Central/south Texas
Austin, Texas, United States
Recruiting
Virginia Cancer Specialists
Fairfax, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

WSD0922-FU Tablets, Dose level AWSD0922-FU Tablets, Dose level B

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Aug 2025
Primary completion: 30 Sept 2027
Completion: 31 Dec 2027
Last update posted: 8 Sept 2025
Registered enrollment: 40
Registry id: NCT06868485

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.